The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats

Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990, 347 (6294): 645-650. 10.1038/347645a0. Chang F, Jaber LA, Berlie HD, O'Connell MB: Evolution of peroxisome proliferator-activated receptor agonists. Ann Pharmacother. 2007, 41 (6): 973-983. 10.1345/aph.1K013. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S: International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 2006, 58 (4): 726-741. 10.1124/pr.58.4.5. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med. 2002, 53: 409-435. 10.1146/annurev.med.53.082901.104018. Lemberger T, Braissant O, Juge-Aubry C, Keller H, Saladin R, Staels B, Auwerx J, Burger AG, Meier CA, Wahli W: PPAR tissue distribution and interactions with other hormone-signaling pathways. Ann N Y Acad Sci. 1996, 804: 231-251. 10.1111/j.1749-6632.1996.tb18619.x. Berger JP, Akiyama TE, Meinke PT: PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci. 2005, 26 (5): 244-251. 10.1016/j.tips.2005.03.003. Forman BM, Chen J, Evans RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA. 1997, 94 (9): 4312-4317. 10.1073/pnas.94.9.4312. Rao MS, Reddy JK: Peroxisome proliferation and hepatocarcinogenesis. Carcinogenesis. 1987, 8 (5): 631-636. 10.1093/carcin/8.5.631. Still K, Grabowski P, Mackie I, Perry M, Bishop N: The Peroxisome Proliferator Activator Receptor Alpha/Delta Agonists Linoleic Acid and Bezafibrate Upregulate Osteoblast Differentiation and Induce Periosteal Bone Formation In Vivo. Calcif Tissue Int. 2008 Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996, 45 (12): 1661-1669. 10.2337/diabetes.45.12.1661. Giaginis C, Tsantili-Kakoulidou A, Theocharis S: Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. Fundam Clin Pharmacol. 2007, 21 (3): 231-244. 10.1111/j.1472-8206.2007.00486.x. Syversen U, Aune G, Thommesen L: PPAR-Alpha Agonists Increase Bone Mineral Density in Female Rats. Abstract at ASBMR 25th Annual Meeting. 2003, Minneapolis, Minnesota, USA Syversen U, Stunes AK, Gustafsson BI, Obrant KJ, Nordsletten L, Berge R, Thommesen L, Reseland JE: Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr Disord. 2009, 9: 10-10.1186/1472-6823-9-10. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL: Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology. 2002, 143 (6): 2376-2384. 10.1210/en.143.6.2376. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL: Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem. 1999, 74 (3): 357-371. 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7. Khan E, Abu-Amer Y: Activation of peroxisome proliferator-activated receptor-gamma inhibits differentiation of preosteoblasts. J Lab Clin Med. 2003, 142 (1): 29-34. 10.1016/S0022-2143(03)00058-1. Kawaguchi H, Akune T, Yamaguchi M, Ohba S, Ogata N, Chung UI, Kubota N, Terauchi Y, Kadowaki T, Nakamura K: Distinct effects of PPARgamma insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells. J Bone Miner Metab. 2005, 23 (4): 275-279. 10.1007/s00774-005-0599-2. Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM, Morris DC: Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol. 1996, 50 (5): 1087-1094. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K: PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004, 113 (6): 846-855. Okazaki R, Toriumi M, Fukumoto S, Miyamoto M, Fujita T, Tanaka K, Takeuchi Y: Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology. 1999, 140 (11): 5060-5065. 10.1210/en.140.11.5060. Mbalaviele G, Abu-Amer Y, Meng A, Jaiswal R, Beck S, Pittenger MF, Thiede MA, Marshak DR: Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem. 2000, 275 (19): 14388-14393. 10.1074/jbc.275.19.14388. Chan BY, Gartland A, Wilson PJ, Buckley KA, Dillon JP, Fraser WD, Gallagher JA: PPAR agonists modulate human osteoclast formation and activity in vitro. Bone. 2007, 40 (1): 149-159. 10.1016/j.bone.2006.07.029. Bendixen AC, Shevde NK, Dienger KM, Willson TM, Funk CD, Pike JW: IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci USA. 2001, 98 (5): 2443-2448. 10.1073/pnas.041493198. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC: Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol. 2004, 183 (1): 203-216. 10.1677/joe.1.05723. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology. 2004, 145 (1): 401-406. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL: Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005, 146 (3): 1226-1235. Sottile V, Seuwen K, Kneissel M: Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int. 2004, 75 (4): 329-337. 10.1007/s00223-004-0224-8. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B: Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology. 2007, 148 (6): 2669-2680. 10.1210/en.2006-1587. Li M, Pan LC, Simmons HA, Li Y, Healy DR, Robinson BS, Ke HZ, Brown TA: Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice. Bone. 2006, 39 (4): 796-806. 10.1016/j.bone.2006.04.008. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA: Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006, 91 (9): 3349-3354. 10.1210/jc.2005-2226. Yaturu S, Bryant B, Jain SK: Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care. 2007, 30 (6): 1574-1576. 10.2337/dc06-2606. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006, 355 (23): 2427-2443. 10.1056/NEJMoa066224. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR: The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007, 92 (4): 1305-1310. 10.1210/jc.2006-2646. Seeman E, Delmas PD: Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med. 2006, 354 (21): 2250-2261. 10.1056/NEJMra053077. Muller R: Long-term prediction of three-dimensional bone architecture in simulations of pre-, peri- and post-menopausal microstructural bone remodeling. Osteoporos Int. 2005, 16 (Suppl 2): S25-35. Boutroy S, Bouxsein ML, Munoz F, Delmas PD: In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2005, 90 (12): 6508-6515. 10.1210/jc.2005-1258. Sedova L, Seda O, Krenova D, Kren V, Kazdova L: Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome. Int J Obes Relat Metab Disord. 2004, 28 (5): 719-725. 10.1038/sj.ijo.0802613. Pathan AR, Viswanad B, Sonkusare SK, Ramarao P: Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci. 2006, 79 (23): 2209-2216. 10.1016/j.lfs.2006.07.018. Lenhard JM, Croom DK, Minnick DT: Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Commun. 2004, 324 (1): 92-97. 10.1016/j.bbrc.2004.09.021. Westbroek I, Waarsing JH, van Leeuwen JP, Waldum H, Reseland JE, Weinans H, Syversen U, Gustafsson BI: Long-term fluoxetine administration does not result in major changes in bone architecture and strength in growing rats. J Cell Biochem. 2006 Odgaard A, Gundersen HJ: Quantification of connectivity in cancellous bone, with special emphasis on 3-D reconstructions. Bone. 1993, 14 (2): 173-182. 10.1016/8756-3282(93)90245-6. Hildebrand T, Ruegsegger P: Quantification of Bone Microarchitecture with the Structure Model Index. Comput Methods Biomech Biomed Engin. 1997, 1 (1): 15-23. 10.1080/01495739708936692. Nordsletten L, Kaastad TS, Obrant KJ, Skjeldal S, Kirkeby OJ, Stokke O, Ekeland A: Muscle contraction increases the in vivo structural strength to the same degree in osteopenic and normal rat tibiae. J Bone Miner Res. 1994, 9 (5): 679-685. Dobson KR, Reading L, Haberey M, Marine X, Scutt A: Centrifugal isolation of bone marrow from bone: an improved method for the recovery and quantitation of bone marrow osteoprogenitor cells from rat tibiae and femurae. Calcif Tissue Int. 1999, 65 (5): 411-413. 10.1007/s002239900723. Scutt A, Reading L, Scutt N, Still K: Mineralizing fibroblast-colony-forming assays. Methods Mol Med. 2003, 80: 29-39. Kharode YP, Sharp MC, Bodine PV: Utility of the ovariectomized rat as a model for human osteoporosis in drug discovery. Methods Mol Biol. 2008, 455: 111-124. 10.1007/978-1-59745-104-8_8. Leppanen OV, Sievanen H, Jokihaara J, Pajamaki I, Kannus P, Jarvinen TL: Pathogenesis of age-related osteoporosis: impaired mechano-responsiveness of bone is not the culprit. PLoS One. 2008, 3 (7): e2540-10.1371/journal.pone.0002540. Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N: Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol. 2005, 23 (3): 323-330. Celinska-Lowenhoff M, Lowenhoff T, Undas A, Gluszko P: Effects of hypolipemic drugs on the osteoprotegerin - sRANKL system in patients with coronary artery disease. Thromb Haemost. 2007, 97 (5): 868-870. Jackson SM, Demer LL: Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett. 2000, 471 (1): 119-124. 10.1016/S0014-5793(00)01372-7. Yamazaki K, Kuromitsu J, Tanaka I: Microarray Analysis of Gene Expression Changes in Mouse Liver Induced by Peroxisome Proliferator- Activated Receptor [alpha] Agonists. Biochem Biophys Res Commun. 2002, 290 (3): 1114-1122. 10.1006/bbrc.2001.6319. Grey A: Skeletal consequences of thiazolidinedione therapy. Osteoporos Int. 2008, 19 (2): 129-137. 10.1007/s00198-007-0477-y. Schwartz AV: Diabetes, TZDs, and Bone: A Review of the Clinical Evidence. PPAR Res. 2006, 2006: 24502- Cohen D: Rosiglitazone: what went wrong?. BMJ. 2010, 341: c4848-10.1136/bmj.c4848. Hung SH, Yeh CH, Huang HT, Wu P, Ho ML, Chen CH, Wang C, Chao D, Wang GJ: Pioglitazone and dexamethasone induce adipogenesis in D1 bone marrow stromal cell line, but not through the peroxisome proliferator-activated receptor-gamma pathway. Life Sci. 2008, 82 (11-12): 561-569. 10.1016/j.lfs.2007.11.033. Hasegawa T, Oizumi K, Yoshiko Y, Tanne K, Maeda N, Aubin JE: The PPARgamma-selective ligand BRL-49653 differentially regulates the fate choices of rat calvaria versus rat bone marrow stromal cell populations. BMC Dev Biol. 2008, 8: 71-10.1186/1471-213X-8-71. Hounoki H, Sugiyama E, Mohamed SG, Shinoda K, Taki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Miyahara T: Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression. Bone. 2008, 42 (4): 765-774. 10.1016/j.bone.2007.11.016. Wan Y, Chong LW, Evans RM: PPAR-gamma regulates osteoclastogenesis in mice. Nat Med. 2007, 13 (12): 1496-1503. 10.1038/nm1672. Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A: Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther. 2006, 28 (5): 679-688. 10.1016/j.clinthera.2006.05.012. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005, 28 (7): 1547-1554. 10.2337/diacare.28.7.1547. Khan MA, St Peter JV, Xue JL: A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2002, 25 (4): 708-711. 10.2337/diacare.25.4.708. Jeon MJ, Kim JA, Kwon SH, Kim SW, Park KS, Park SW, Kim SY, Shin CS: Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts. J Biol Chem. 2003, 278 (26): 23270-23277. 10.1074/jbc.M211610200. Gomez-Ambrosi J, Rodriguez A, Catalan V, Fruhbeck G: The bone-adipose axis in obesity and weight loss. Obes Surg. 2008, 18 (9): 1134-1143. 10.1007/s11695-008-9548-1. Reid IR: Relationships between fat and bone. Osteoporos Int. 2007 Zhao LJ, Jiang H, Papasian CJ, Maulik D, Drees B, Hamilton J, Deng HW: Correlation of Obesity and Osteoporosis - Effect of Fat Mass on the Determination of Osteoporosis. J Bone Miner Res. 2007 Shinoda Y, Yamaguchi M, Ogata N, Akune T, Kubota N, Yamauchi T, Terauchi Y, Kadowaki T, Takeuchi Y, Fukumoto S: Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem. 2006, 99 (1): 196-208. 10.1002/jcb.20890. Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, Syversen U, Reseland JE: Adiponectin and its receptors are expressed in bone-forming cells. Bone. 2004, 35 (4): 842-849. 10.1016/j.bone.2004.06.008. Reseland JE, Syversen U, Bakke I, Qvigstad G, Eide LG, Hjertner O, Gordeladze JO, Drevon CA: Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res. 2001, 16 (8): 1426-1433. 10.1359/jbmr.2001.16.8.1426. Gordeladze JO, Drevon CA, Syversen U, Reseland JE: Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: Impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem. 2002, 85 (4): 825-836. 10.1002/jcb.10156. Banks WA: The many lives of leptin. Peptides. 2004, 25 (3): 331-338. 10.1016/j.peptides.2004.02.014. Fruhbeck G: Intracellular signalling pathways activated by leptin. Biochem J. 2006, 393 (Pt 1): 7-20. Galisteo M, Sanchez M, Vera R, Gonzalez M, Anguera A, Duarte J, Zarzuelo A: A diet supplemented with husks of Plantago ovata reduces the development of endothelial dysfunction, hypertension, and obesity by affecting adiponectin and TNF-alpha in obese Zucker rats. J Nutr. 2005, 135 (10): 2399-2404. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, Simon I, Soler J, Richart C: Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res. 2004, 12 (6): 962-971. 10.1038/oby.2004.118. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001, 86 (5): 1930-1935. 10.1210/jc.86.5.1930. Riera-Guardia N, Rothenbacher D: The effect of thiazolidinediones on adiponectin serum level: a meta-analysis. Diabetes Obes Metab. 2007 Sharabi Y, Oron-Herman M, Kamari Y, Avni I, Peleg E, Shabtay Z, Grossman E, Shamiss A: Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model. Am J Hypertens. 2007, 20 (2): 206-210. 10.1016/j.amjhyper.2006.08.002. Yang G, Li L, Tang Y, Boden G: Short-term pioglitazone treatment prevents free fatty acid-induced hepatic insulin resistance in normal rats: possible role of the resistin and adiponectin. Biochem Biophys Res Commun. 2006, 339 (4): 1190-1196. 10.1016/j.bbrc.2005.11.143. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6823/11/11/prepub